(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/122134 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61K 31/498* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2022/053582

(22) International Filing Date:
21 December 2022 (21.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/292,628 22 December 2021 (22.12.2021) US

(71) Applicant: **INCYTE CORPORATION** [US/US]; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventors: **LIU, Pingli**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **JIA, Zhongjiang**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **LIN, Qiyan**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **SU, Naijing**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **MARTIN, Timothy**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **XIA, Michael**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **ZHOU, Jiacheng**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **MI, Baoyu**; Pencader Corporate Center, 229A Lake Drive, Newark, Delaware 19702 (US).

(74) Agent: **SEARS, Justin Edward** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2023/122134 A1

(54) **Title:** SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES OF PREPARING THEREOF

(57) **Abstract:** The present invention relates to salts and solid forms of the FGFR inhibitor(7*R*,8a*S*)-2-(5-(5-(2,3-Dimethylphenyl)-6-methoxy-1*H*-pyrazolo[4,3-*b*]pyridin-3-yl)pyridin-2-yl)octahydropyrrolo[1,2-*a*]pyrazin-7-ol, including methods of preparation thereof, wherein the compounds, salts, and solid forms are useful in the treatment of FGFR-mediated diseases such as cancer.